Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Receives CE Mark for Hematopoietic Cell Transplantation Testing Kit, Analysis Software

NEW YORK – CareDx announced on Tuesday that it has received CE marking for the AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software, both used in patients who have undergone hematopoietic cell transplantation.

The next-generation sequencing-based test measures the relative ratio of recipient-to-donor cell populations post-transplantation, targeting 202 bi-allelic single-nucleotide polymorphisms across 22 autosomes.

"This new CE mark demonstrates our commitment to bringing high quality products to patients in Europe through our AlloSeq franchise, which includes a comprehensive suite of pre- and post-transplant solutions," Reg Seeto, CEO and president of CareDx, said in a statement.

AlloSeq HCT is part of the firm's wider expansion from organ monitoring into cell transplant monitoring. The company launched AlloCell, a surveillance tool for patients receiving engineered cell transplants, in 2020, and presented data on both that product and AlloSeq HCT at the Transplantation and Cell Therapy conference last year.

Last year, CareDx also acquired European software firm BFS Molecular, a company dedicated to tracking transplanted organ and stem cell health via next-generation sequencing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.